Jazz Pharmaceuticals Finalises Chimerix Acquisition, Expands Oncology Pipeline With Dordaviprone

Jazz Pharmaceuticals has announced the official completion of its $935 million acquisition of Chimerix, Inc., making Chimerix its wholly owned subsidiary. This strategic move strengthens Jazz’s oncology pipeline with the addition of dordaviprone, a first-in-class small-molecule therapy currently in development for H3 K27M-mutant diffuse glioma, a rare and aggressive form of brain cancer.

"Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs," said Bruce Cozadd, chairman and chief executive officer of Jazz. "Dordaviprone has the potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and offers a promising near-term commercial opportunity, if approved. We are excited to welcome Chimerix's talented team as we continue to advance dordaviprone, leveraging our development and commercial capabilities to deliver this therapy to patients as soon as the second half of this year."

The FDA has placed dordaviprone under Priority Review the with a decision expected by August 18, 2025. The therapy can acquire a Rare Pediatric Disease Priority Review Voucher that would expeditiously release it to market upon approval. Dordaviprone moves forward with Phase 3 clinical trial (ACTION) evaluation for its application as a potential treatment for newly diagnosed non-recurrent patients who have finished radiation therapy.